In August, 2014, enlighten received clearance for the treatment of benign pigmented lesions.
"The FDA clearance for tattoo removal for enlighten signifies a critical milestone not only for Cutera, but for the advancement of picosecond laser technology in the aesthetics market. Consistent with our innovative design philosophy, enlighten features industry-leading laser and optical design with advanced micro-electronics," said Kevin Connors, President and CEO of Cutera.
"The use of picosecond laser technology in aesthetic practices is evolving. With enlighten, practitioners are much closer to utilizing a single device for the vast majority of tattoo removal procedures," said Michael S. Kaminer, M.D., a board certified Dermatologist and Managing Partner of SkinCare Physicians in Chestnut Hill, Massachusetts, and one of the pre-eminent educators in cosmetic and aesthetic surgery.
Commercial shipments of enlighten are anticipated to commence in the fourth quarter, 2014.
Brisbane, California-based Cutera is a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide.
Since 1998, Cutera has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients.
